Outgoing Perrigo Co. PLC CEO John Hendrickson continued to express confidence that the company should stay in the Rx generic topical business, even though that view likely influenced his pending exit after little more than a year leading the OTC private label giant.
His departure is one more step making it more likely that Perrigo will divest the Rx unit and focus more
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?